Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment
- PMID: 16950977
- DOI: 10.1542/peds.2006-0413
Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment
Abstract
Objectives: Infantile hemangiomas are the most common tumor of infancy. Risk factors for complications and need for treatment have not been studied previously in a large prospective study. This study aims to identify clinical characteristics associated with complications and the need for therapeutic intervention.
Patients and methods: We conducted a prospective cohort study at 7 US pediatric dermatology clinics with a consecutive sample of 1058 children, aged < or = 12 years, with infantile hemangiomas enrolled between September 2002 and October 2003. A standardized questionnaire was used to collect data on each patient and each hemangioma, including clinical characteristics, complications, and treatment.
Results: Twenty-four percent of patients experienced complications related to their hemangioma(s), and 38% of our patients received some form of treatment during the study period. Hemangiomas that had complications and required treatment were larger and more likely to be located on the face. Segmental hemangiomas were 11 times more likely to experience complications and 8 times more likely to receive treatment than localized hemangiomas, even when controlled for size.
Conclusions: Large size, facial location, and/or segmental morphology are the most important predictors of poor short-term outcomes as measured by complication and treatment rates.
Similar articles
-
Growth characteristics of infantile hemangiomas: implications for management.Pediatrics. 2008 Aug;122(2):360-7. doi: 10.1542/peds.2007-2767. Pediatrics. 2008. PMID: 18676554
-
Risk Factors for Degree and Type of Sequelae After Involution of Untreated Hemangiomas of Infancy.JAMA Dermatol. 2016 Nov 1;152(11):1239-1243. doi: 10.1001/jamadermatol.2016.2905. JAMA Dermatol. 2016. PMID: 27540637
-
Infantile Hemangioma: An Updated Review.Curr Pediatr Rev. 2021;17(1):55-69. doi: 10.2174/1573396316666200508100038. Curr Pediatr Rev. 2021. PMID: 32384034 Review.
-
Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics.J Pediatr. 2007 Mar;150(3):291-4. doi: 10.1016/j.jpeds.2006.12.003. J Pediatr. 2007. PMID: 17307549
-
Risk stratification in hemangiomas of infancy.Lymphat Res Biol. 2003;1(4):313-6. doi: 10.1089/153968503322758120. Lymphat Res Biol. 2003. PMID: 15624560 Review.
Cited by
-
Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma.Eur J Pediatr. 2015 Nov;174(11):1503-9. doi: 10.1007/s00431-015-2561-1. Epub 2015 May 16. Eur J Pediatr. 2015. PMID: 25982338 Clinical Trial.
-
miR‑139‑5p affects cell proliferation, migration and adipogenesis by targeting insulin‑like growth factor 1 receptor in hemangioma stem cells.Int J Mol Med. 2020 Feb;45(2):569-577. doi: 10.3892/ijmm.2019.4430. Epub 2019 Dec 17. Int J Mol Med. 2020. PMID: 31894289 Free PMC article.
-
Infantile Haemangioma in the Romanian Paediatric Population-Characteristics and Therapeutic Approaches.Children (Basel). 2023 Jul 30;10(8):1314. doi: 10.3390/children10081314. Children (Basel). 2023. PMID: 37628313 Free PMC article.
-
Global research trends of infantile hemangioma: A bibliometric and visualization analysis from 2000 to 2022.Heliyon. 2023 Oct 21;9(11):e21300. doi: 10.1016/j.heliyon.2023.e21300. eCollection 2023 Nov. Heliyon. 2023. PMID: 37920523 Free PMC article.
-
Subglottic hemangioma treated with propranolol.Eplasty. 2014 Jan 15;14:ic2. eCollection 2014. Eplasty. 2014. PMID: 24501622 Free PMC article. No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical